The plasmacytoid carcinoma of the bladder-rare variant of aggressive urothelial carcinoma

Department of Urology, University Erlangen, Erlangen, Germany.
International Journal of Cancer (Impact Factor: 5.01). 07/2011; 129(2):346-54. DOI: 10.1002/ijc.25700
Source: PubMed

ABSTRACT The WHO 2004 classification defines new histological and molecular variants of urothelial carcinoma. However, there are limited data available on the clinicopathological characteristics or prognosis of these variants. We present histopathological, molecular and clinical data of 32 plasmacytoid carcinomas of the bladder (PUC) showing that PUC is a high-grade tumor with molecular features of aggressive urothelial carcinoma, usually diagnosed in advanced pathological stage (64% pT3, 23% pT4) showing metastases in 60% of the patients. Average survival of our cohort of PUC treated with radical cystectomy and adjuvant chemotherapy was lower than what is typically seen for comparable conventional urothelial carcinomas. Eighty-seven percent of the PUCs showed a negative or strongly reduced membranous staining of E-cadherin. β-Catenin staining was negative in 22.5%, and 16.7% of the remaining tumors showed nuclear accumulation. Aberrant CK20 expression (negative or >10% of cells stained) and negative CK7 staining was found in 100% and 22.6%, respectively. Ninety-seven percent revealed positive staining for PAN-CK. CD138 was positive in 78%, whereas MUM-1 expression was negative in all cases. Multitarget fluorescence in situ hybridization showed all PUCs to be highly aneuploid and polysomic. Deletions on chromosome 9p21 seem to play an important role in this variant. FGFR3 and PIK3CA mutation analyses yielded no mutations in any of the PUCs analyzed. TP53 mutation analysis showed mutations in 29%. In summary, PUC is an aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases.

Download full-text


Available from: Antonio Lopez-Beltran, Oct 13, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Plasmacytoid urothelial carcinoma (PUC) of the bladder is a rare histological variant of urothelial carcinoma that was recently identified. Available data on this histological variant is limited. Case Report. We report the case of a 75-year-old man with presumed history of high-grade urothelial cancer of the bladder, treated with transurethral resection and Bacille Calmette-Guérin (BCG) in 2004. Six years after treatment of the bladder cancer, the patient underwent gastrectomy for an undifferentiated carcinoma of the stomach. On followup, patient developed right ureterohydronephrosis and peritoneal carcinomatosis. Biopsy of the bladder during stent placement revealed a plasmacytoid urothelial carcinoma of the bladder. Rereadings revealed that the initial bladder and gastric malignancies were also plasmacytoid carcinoma, indicating that, the patient had since 2004, a PUC of the bladder that spread to the stomach and peritoneal cavity. Conclusion. Plasmacytoid urothelial carcinoma of the bladder is an aggressive variant of urothelial carcinoma. Based on our case and the literature review, this tumor can be misdiagnosed because of its rarity, leading to treatment delays. Both the urologist and the pathologist need to have a high index of suspicion for PUC whenever they encounter unusual clinical and/or pathological findings.
    08/2012; 2012:715951. DOI:10.1155/2012/715951
  • Advances in Experimental Medicine and Biology 02/2002; 506(Pt A):629-39. · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Das plasmazytoide Urothelkarzinom (PUC) zählt neben dem mikropapillären (MPC), kleinzelligen und dem Tumor vom „nested-type“ zu den seltenen Varianten von Urothelkarzinomen. Die molekulare Charakterisierung von PUC und MPC stellt dabei gegenwärtig unser Forschungsschwerpunkt im Bereich Harnblasenkarzinom dar, welchen wir in Kooperation mit dem Pathologischen Institut Erlangen verfolgen. PUC betreffen ca. 0,9% aller Urothelkarzinome. Die Diagnose solcher seltenen Varianten erlangt immer mehr an Bedeutung, da sich daraus prognostische und möglicherweise auch therapeutische Konsequenzen für den Patienten ergeben. In einer Analyse von 32 PUC konnten wir die bisher umfassendsten Ergebnisse zu grundlegenden molekularen und klinischen Charakteristika dieser Variante präsentieren. MPC wurden bereits in multiplen Organen beschrieben. Mikropapilläre Karzinome der Mamma stellen dabei eine eigene Entität mit charakteristischen genomischen Aberrationen und entsprechenden klinischen und pathologischen Eigenschaften dar. Plasmacytoid urothelial carcinomas (PUC) along with micropapillary urothelial carcinoma (MPC), small cell cancer, and nested-typed tumors are among the rare variations of urothelial carcinomas. The molecular characterization of PUC and MPC is currently the focus of our research on bladder cancer which we are conducting in cooperation with the Institute of Pathology in Erlangen. PUCs account for approximately 0.9% of all urothelial carcinomas. The diagnosis of these rare variants has acquired increasing importance since this may have prognostic and possibly therapeutic consequences for the patients. By analysis of 32 PUCs we were able to demonstrate the most comprehensive results available to date on the underlying molecular and clinical characteristics of these variants. Micropapillary cancers have already been described in multiple organs. Micropapillary breast cancer represent an individual entity with characteristic genomic aberrations and corresponding clinical and pathological features SchlüsselwörterPlasmazytoides Urothelkarzinom–Mikropapilläres Urothelkarzinom–Aberrationen–Histomorphologie–Harnblase KeywordsPlasmacytoid urothelial carcinoma–Micropapillary urothelial carcinoma–Aberrations–Histomorphology–Urinary bladder
    Der Urologe 02/2011; 50(2):217-220. DOI:10.1007/s00120-010-2484-4 · 0.44 Impact Factor